FOLH1 and prostate carcinoma: The formed nanoparticles were directed toward prostate cancer cells overexpressing prostate-specific membrane antigen (PSMA) receptors, by using the PSMA ligand S,S-2-(3-[5-amino-1-carboxypentyl]-ureido)pentanedioic acid.